Nintedanib Eurogenerics (Nintedanib)

Nintedanib is an antifibrotic and anti‑angiogenic agent indicated for several progressive lung disorders.

• Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression.
• Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and delays respiratory deterioration.
• Non‑small cell lung cancer (in combination therapy): inhibits tumor cell proliferation and angiogenesis, contributing to disease control.

• Nintedanib inhibits multiple receptor tyrosine kinases—including vascular endothelial growth factor receptors (VEGFR 1‑3), fibroblast growth factor receptors (FGFR 1‑3) and platelet‑derived growth factor receptors (PDGFR‑α/β). By blocking these pathways, it reduces fibroblast activation, extracellular matrix deposition, and pathological angiogenesis, thereby attenuating fibrotic remodeling and tumor growth.

Nintedanib may cause a range of adverse reactions, most of which are manageable with monitoring and supportive care.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: sensation of unease or urge to vomit.
• Vomiting: expulsion of stomach contents.
• Abdominal pain: discomfort or cramping in the stomach area.
• Decreased appetite: reduced desire to eat.
• Headache: mild to moderate head pain.

Serious or Rare Side Effects

• Elevated liver enzymes: potential indication of hepatic injury.
• Bleeding events: including gastrointestinal or pulmonary hemorrhage.
• Cardiovascular events: such as hypertension or myocardial infarction.
• Severe infections: opportunistic or bacterial infections requiring medical attention.
• Gastrointestinal perforation: rare but serious tearing of the GI tract.
• Interstitial lung disease worsening: rare exacerbation of underlying lung disease.

Before initiating therapy, clinicians should assess patient suitability and monitor for specific risks.

• Liver function monitoring: check ALT/AST levels regularly.
• Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet use.
• Cardiovascular evaluation: screen for hypertension or cardiac disease.
• Gastrointestinal symptom management: advise patients to report persistent diarrhea or abdominal pain.
• Avoid use in severe hepatic impairment: contraindicated when liver function is markedly compromised.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nintedanib interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.
• Antiplatelet agents (e.g., aspirin, clopidogrel): additive hemorrhagic potential.
• P‑gp inhibitors (e.g., verapamil, quinidine): can raise plasma concentrations.
• High‑dose aspirin (>325 mg/day): may exacerbate gastrointestinal toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Diuretics: monitor electrolytes and renal function.
• NSAIDs: increase risk of gastrointestinal bleeding.
• Proton‑pump inhibitors: may affect absorption, watch for reduced efficacy.
• Herbal supplements (e.g., St John’s wort): potential CYP3A4 induction.